首次出版:最新修订:March 2009交付方式:特快专递(2-3天送达)
定购电话:0755-82571522、82571566、400-008-1522
24小时服务热线:138 0270 8576定制报告
版本 | 在线版 | 电子版或印刷版 | 电子版+印刷版 |
---|---|---|---|
优惠价 | RMB 6800 | RMB 7600 | RMB 7800 |
原价 | RMB 9600 | RMB 9600 | RMB 9800 |
订购报告,即可获得以下权益:
权益一:加1送1——加1000元、送1份在线版研究报告,多加多送,数量不限; 了解在线版报告详细清单,请点击咨询 >
权益二:加1送2——加1000元,送2个独家数据库,即上市公司投资项目库和企业拿地投资数据库;了解中投大数据 >
权益三:加1送200——加1000元,送超过200条在线版产业链图谱,使用期限为1年;查看产业链图谱清单 >
重磅推出产业研究大脑,是"产业研究的数字化高效工具",欢迎试用体验! |
||||
---|---|---|---|---|
产品名称 | 目标用户 | 核心功能定位 | 产品介绍 | 试用申请 |
产业研究大脑 | 政府、企业内关注产业发展的领导及工作人员 | 产业研究工作的一站式解决方案 | 详情 > | 申请 > |
联系电话:400 008 0586; 0755-82571568
微信扫码:
Chapter1
ExecutiveSummary
ExecutiveSummary1-1
ExecutiveSummary1-1
Chapter2
TotalU.S.OpioidandNon-OpioidPainManagementPharmaceuticalsMarkets
MarketOverview2-1
Introduction2-1
ScopeandSegmentation2-2
ResearchMethodology2-3
Methodology2-4
BaseYearMarketAssumptions2-4
RestraintsinForecasts2-4
MarketEngineeringMeasurements2-4
MarketForecasts2-5
PatientForecasts2-5
PricingForecasts2-8
RevenueForecasts2-11
CompetitiveAnalysis2-13
MarketShareAnalysis2-13
ProductPipeline2-17
OpioidPainManagementPharmaceuticals2-17
Non-OpioidPainManagementPharmaceuticals2-18
Chapter3
U.S.OpioidPainManagementPharmaceuticalsMarket
MarketOverview3-1
Introduction3-1
MarketEngineeringMeasurements3-2
MarketAge3-3
Revenues3-3
PotentialRevenues3-3
BaseYearMarketGrowthRate3-3
CompoundAnnualGrowthRate3-3
Saturation3-4
AverageCostperPatient3-4
AverageCostperDay3-4
PriceSensitivity3-4
TotalPotentialPatients3-4
Competitors3-4
DegreeofCompetition3-5
DegreeofTechnicalChange3-5
MarketConcentration3-5
MarketForecasts3-5
PatientForecasts3-5
PricingForecasts3-7
RevenueForecasts3-10
CompetitiveAnalysis3-12
CompetitiveStructure3-12
MarketShareAnalysis3-13
Chapter4
U.S.Non-OpioidPainManagementPharmaceuticalsMarket
MarketOverview4-1
Introduction4-1
MarketEngineeringMeasurements4-2
MarketAge4-3
Revenues4-3
PotentialRevenues4-3
BaseYearMarketGrowthRate4-3
CompoundAnnualGrowthRate4-3
Saturation4-4
AverageCostperPatient4-4
AverageCostperDay4-4
PriceSensitivity4-4
TotalPotentialPatients4-4
Competitors4-4
DegreeofCompetition4-5
DegreeofTechnicalChange4-5
MarketForecasts4-5
PatientForecasts4-5
PricingForecasts4-7
RevenueForecasts4-9
CompetitiveAnalysis4-11
CompetitiveStructure4-11
MarketShareAnalysis4-12
Chapter5
DecisionSupportDatabases
DiseaseIncidence5-1
ArthritisPrevalence5-1
DemographicIndicators5-3
PopulationAbove655-3
PercentofPopulationAbove655-6
MalePopulationAbove655-8
FemalePopulationAbove655-11
MarketIndicator5-13
OTCasPercentofTotalPharma5-13
ListofFigures
Chapter2
TotalU.S.OpioidandNon-OpioidPainManagementPharmaceuticalsMarkets
2-1TotalOpioidandNon-OpioidPainManagementPharmaceuticalsMarket:
PatientForecasts(U.S.),2003-20132-6
2-2TotalOpioidandNon-OpioidPainManagementPharmaceuticalsMarket:
PatientPenetrationbyProductType(U.S.),2003-20132-7
2-3TotalOpioidandNon-OpioidPainManagementPharmaceuticalsMarket:
AverageCostperPatientForecasts(U.S.),2003-20132-9
2-4TotalOpioidandNon-OpioidPainManagementPharmaceuticalsMarket:
AverageCostofTreatmentperDayForecasts(U.S.),2003-20132-10
2-5TotalOpioidandNon-OpioidPainManagementPharmaceuticalsMarket:
RevenueForecasts(U.S.),2003-20132-12
2-6TotalOpioidandNon-OpioidPainManagementPharmaceuticalsMarket:
PercentofRevenuesbyProductType(U.S.),2003-20132-13
2-7TotalOpioidandNon-OpioidPainManagementPharmaceuticalsMarket:
PercentofPatientsbyProductType(U.S.),2003-20132-14
2-8TotalOpioidandNon-OpioidPainManagementPharmaceuticalsMarket:
MarketShareTrendsofMajorMarketParticipants(U.S.),20062-16
2-9TotalOpioidandNon-OpioidPainManagementPharmaceuticalsMarket:
MajorPipelineProducts(U.S.),20062-17
Chapter3
U.S.OpioidPainManagementPharmaceuticalsMarket
3-1OpioidPainManagementPharmaceuticalsMarket:
PatientForecasts(U.S.),2003-20133-6
3-2OpioidPainManagementPharmaceuticalsMarket:
AverageCostperPatientForecasts(U.S.),2003-20133-8
3-3OpioidPainManagementPharmaceuticalsMarket:
AverageCostperDayForecasts(U.S.),2003-20133-9
3-4OpioidPainManagementPharmaceuticalsMarket:
RevenueForecasts(U.S.),2003-20133-11
3-5OpioidPainManagementPharmaceuticalsMarket:
CompetitiveStructure(U.S.),20063-12
3-6OpioidPainManagementPharmaceuticalsMarket:
RevenueForecastsbyProductType(U.S.),2003-20133-14
3-7OpioidPainManagementPharmaceuticalsMarket:
PercentofRevenuesbyProductType(U.S.),2003-20133-15
3-8OpioidPainManagementPharmaceuticalsMarket:
PercentofPatientsbyProductType(U.S.),2003-20133-16
3-9OpioidPainManagementPharmaceuticalsMarket:
MarketShareTrendsofMajorMarketParticipants(U.S.),2005-20063-18
3-10OpioidPainManagementPharmaceuticalsMarket:
MajorDrugDeliveryPartnerships(U.S.),2005and20063-18
Chapter4
U.S.Non-OpioidPainManagementPharmaceuticalsMarket
4-1Non-OpioidPainManagementPharmaceuticalsMarket:
PatientForecasts(U.S.),2003-20134-5
4-2Non-OpioidPainManagementPharmaceuticalsMarket:
AverageCostperPatientForecasts(U.S.),2003-20134-7
4-3Non-OpioidPainManagementPharmaceuticalsMarket:
AverageCostperDayForecasts(U.S.),2003-20134-8
4-4Non-OpioidPainManagementPharmaceuticalsMarket:
RevenueForecasts(U.S.),2003-20134-10
4-5Non-OpioidPainManagementPharmaceuticalsMarket:
CompetitiveStructure(U.S.),20064-11
4-6Non-OpioidPainManagementPharmaceuticalsMarket:
RevenueForecastsbyProductType(U.S.),2003-20134-13
4-7Non-OpioidPainManagementPharmaceuticalsMarket:
PercentofRevenuesbyProductType(U.S.),2003-20134-14
4-8Non-OpioidPainManagementPharmaceuticalsMarket:
DatabaseofNon-SelectiveNSAIDsbyBrandName(U.S.),20064-15
Chapter5
DecisionSupportDatabases
5-1DecisionSupportDatabase:
PrevalenceofArthritisin’000(World),1999-20065-1
5-2DecisionSupportDatabase:
Population65PlusinMn(World),2002-20125-4
5-3DecisionSupportDatabase:
Populationaged65YearsandaboveasapercentageofTotalPopulation
(World),2002-20125-6
5-4DecisionSupportDatabase:
MalePopulation65PlusinMn(World),2002-20125-9
5-5DecisionSupportDatabase:
FemalePopulation65PlusinMn(World),2002-20125-11
5-6DecisionSupportDatabase:
OTCPharmaceuticalMarketaspercentageofTotalPharmaceuticalMarket
(World),1999-20065-14
ListofCharts
Chapter2
TotalU.S.OpioidandNon-OpioidPainManagementPharmaceuticalsMarkets
2.1TotalOpioidandNon-OpioidPainManagementPharmaceuticalsMarket:
MarketSegmentation(U.S.),20062-2
2.2OpioidandNon-OpioidPainManagementPharmaceuticalsMarket:
MarketEngineeringMeasurements(U.S.),20062-5
2.3TotalOpioidandNon-OpioidPainManagementPharmaceuticalsMarket:
PatientForecasts(U.S.),2003-20132-6
2.4TotalOpioidandNon-OpioidPainManagementPharmaceuticalsMarket:
PatientPenetrationbyProductType(U.S.),2003-20132-8
2.5TotalOpioidandNon-OpioidPainManagementPharmaceuticalsMarket:
AverageCostperPatientForecasts(U.S.),2003-20132-10
2.6TotalOpioidandNon-OpioidPainManagementPharmaceuticalsMarket:
AverageCostofTreatmentperDayForecasts(U.S.),2003-20132-11
2.7TotalOpioidandNon-OpioidPainManagementPharmaceuticalsMarket:
RevenueForecasts(U.S.),2003-20132-12
2.8TotalOpioidandNon-OpioidPainManagementPharmaceuticalsMarket:
PercentofRevenuesbyProductType(U.S.),2003-20132-14
2.9TotalOpioidandNon-OpioidPainManagementPharmaceuticalsMarket:
PercentofPatientsbyProductType(U.S.),2003-20132-15
2.10TotalOpioidandNon-OpioidPainManagementPharmaceuticalsMarket:
CompanyMarketSharebyRevenues(U.S.),20062-16
Chapter3
U.S.OpioidPainManagementPharmaceuticalsMarket
3.1OpioidPainManagementPharmaceuticalsMarket:
MarketEngineeringMeasurements(U.S.),20063-2
3.2OpioidPainManagementPharmaceuticalsMarket:
PatientForecasts(U.S.),2003-20133-6
3.3OpioidPainManagementPharmaceuticalsMarket:
AverageCostperPatientForecasts(U.S.),2003-20133-8
3.4OpioidPainManagementPharmaceuticalsMarket:
AverageCostperDayForecasts(U.S.),2003-20133-9
3.5OpioidPainManagementPharmaceuticalsMarket:
RevenueForecasts(U.S.),2003-20133-11
3.6OpioidPainManagementPharmaceuticalsMarket:
RevenueForecastsbyProductType(U.S.),2003-20133-14
3.7OpioidPainManagementPharmaceuticalsMarket:
PercentofRevenuesbyProductType(U.S.),2003-20133-15
3.8OpioidPainManagementPharmaceuticalsMarket:
PercentofPatientsbyProductType(U.S.),2003-20133-16
Chapter4
U.S.Non-OpioidPainManagementPharmaceuticalsMarket
4.1Non-OpioidPainManagementPharmaceuticalsMarket:
MarketEngineeringMeasurements(U.S.),20064-2
4.2Non-OpioidPainManagementPharmaceuticalsMarket:
PatientForecasts(U.S.),2003-20134-6
4.3Non-OpioidPainManagementPharmaceuticalsMarket:
AverageCostperPatientForecasts(U.S.),2003-20134-8
4.4Non-OpioidPainManagementPharmaceuticalsMarket:
AverageCostPerDayForecasts(U.S.),2003-20134-9
4.5Non-OpioidPainManagementPharmaceuticalsMarket:
RevenueForecasts(U.S.),2003-20134-10
4.6Non-OpioidPainManagementPharmaceuticalsMarket:
RevenueForecastsbyProductType(U.S.),2003-20134-14
4.7Non-OpioidPainManagementPharmaceuticalsMarket:
PercentofRevenuesbyProductType(U.S.),2003-20134-15
Pain is a universal human experience. The International Association for the Study of Pain (IASP) defines pain as an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage. Pain may be a symptom of an underlying disease or disorder, or a disorder in its own right.
A pain message is transmitted to the central nervous system (CNS) by special peripheral nervous system (PNS) cells called nociceptors. These receptors are distributed throughout the body and respond to different stimuli depending on the location. For example, nociceptors that extend from the skin are stimulated by sensations such as pressure, temperature, and chemical changes. When a nociceptor is stimulated, neurotransmitters are released within the cell. Neurotransmitters are chemicals found within the nervous system that facilitate nerve cell communication. The nociceptor transmits its signal to nerve cells within the spinal cord, which conveys the pain message to the thalamus, a specific region in the brain.